Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communications Arising
  • Published:

Drug response consistency in CCLE and CGP

This article has been updated

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Consistency between pharmacological data in CCLE and CGP.

Change history

  • 19 July 2017

    The link to the Reply (nature20581) was corrected.

References

  1. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012)

    Article  ADS  CAS  Google Scholar 

  2. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012)

    Article  ADS  CAS  Google Scholar 

  3. Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389–393 (2013)

    Article  ADS  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Marc R. Birtwistle.

Extended data figures and tables

Extended Data Figure 1 Examples of typical sensitive versus insensitive dose–response curves.

This document was given to manual curators as example dose–response curves. These idealized data represent various dose–response curves one might encounter in CCLE and/or CGP and indicate how they should be classified.

Extended Data Figure 2 Examples of what the manual curators received.

This is one page, as an example, from the data given to manual curators, which they were instructed to rate as either sensitive or insensitive.

Supplementary information

Supplementary Information

This file contains Supplementary Methods and Supplementary Data. Each data page depicts a different cancer cell line, the name of which is given at the top of each page. On each page, all of the drugs that were tested by both CCLE and CGP are displayed. Drug dose is on the x-axis and percent cell viability is on the y-axis. Blue corresponds to CCLE and red to CGP. Stars indicate the shared dose range between the two studies. The red and blue numbers in the bottom left corner of each subplot are the means across all manual curator ratings for CGP and CCLE, respectively. 1= unanimous sensitivity; 2=unanimous insensitivity. (PDF 13108 kb)

Supplementary Data 1

Discrepantly classified dose response curves. Dose response curves from drug/ cell line pairs that were discrepant in terms of sensitivity classification. Only data in shared dose range is shown. Red dots are CGP, blue are CCLE. (PDF 1474 kb)

Supplementary Data 2

This zipped file contains Supplementary Data - see -read me’ file for details. (ZIP 464 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bouhaddou, M., DiStefano, M., Riesel, E. et al. Drug response consistency in CCLE and CGP. Nature 540, E9–E10 (2016). https://doi.org/10.1038/nature20580

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature20580

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer